Fundamental Analysis of LUMOS PHARMA INC(NASDAQ:LUMO) stock

Fundamental Rating

Taking everything into account, LUMO scores 3 out of 10 in our fundamental rating. LUMO was compared to 587 industry peers in the Biotechnology industry. While LUMO has a great health rating, there are worries on its profitability. While showing a medium growth rate, LUMO is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year LUMO has reported negative net income.

In the past year LUMO has reported a negative cash flow from operations.

LUMO had negative earnings in each of the past 5 years.

LUMO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

LUMO has a worse Return On Assets (-83.56%) than 72.99% of its industry peers.

The Return On Equity of LUMO (-124.36%) is worse than 61.71% of its industry peers.

		Industry Rank	Sector Rank
ROA	-83.56%
ROE	-124.36%
ROIC	N/A

ROA(3y)-52.36%

ROA(5y)-41.28%

ROE(3y)-70.33%

ROE(5y)-54.18%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

LUMO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LUMO does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for LUMO has been reduced compared to 1 year ago.

Compared to 5 years ago, LUMO has more shares outstanding

LUMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

LUMO has an Altman-Z score of -6.54. This is a bad value and indicates that LUMO is not financially healthy and even has some risk of bankruptcy.

LUMO has a worse Altman-Z score (-6.54) than 69.57% of its industry peers.

LUMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-6.54

ROIC/WACCN/A

WACC9.02%

2.3 Liquidity

LUMO has a Current Ratio of 5.69. This indicates that LUMO is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of LUMO (5.69) is comparable to the rest of the industry.

LUMO has a Quick Ratio of 5.69. This indicates that LUMO is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of LUMO (5.69) is better than 60.34% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.69
Quick Ratio	5.69

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for LUMO have decreased strongly by -12.94% in the last year.

The Revenue has grown by 35.07% in the past year. This is a very strong growth!

LUMO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -30.34% yearly.

EPS 1Y (TTM)-12.94%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-18.18%

Revenue 1Y (TTM)35.07%

Revenue growth 3Y117.26%

Revenue growth 5Y-30.34%

Revenue growth Q2Q65.2%

3.2 Future

LUMO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.16% yearly.

Based on estimates for the next years, LUMO will show a very strong growth in Revenue. The Revenue will grow by 206.70% on average per year.

EPS Next Y31.55%

EPS Next 2Y22.95%

EPS Next 3Y21.41%

EPS Next 5Y40.16%

Revenue Next Year648.83%

Revenue Next 2Y170.99%

Revenue Next 3Y188.56%

Revenue Next 5Y206.7%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

LUMO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LUMO. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

LUMO's earnings are expected to grow with 21.41% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y22.95%

EPS Next 3Y21.41%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LUMO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LUMOS PHARMA INC

NASDAQ:LUMO (5/17/2024, 7:11:38 PM)

2.54

-0.09 (-3.42%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap20.62M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-83.56%
ROE	-124.36%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.05

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	5.69
Quick Ratio	5.69
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-12.94%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y31.55%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)35.07%

Revenue growth 3Y117.26%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

LUMOS PHARMA INC (LUMO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens